TY - JOUR
T1 - Emerging local immunomodulatory strategies to circumvent systemic immunosuppression in cell transplantation
AU - Campa-Carranza, Jocelyn Nikita
AU - Paez-Mayorga, Jesus
AU - Chua, Corrine Ying Xuan
AU - Nichols, Joan E.
AU - Grattoni, Alessandro
N1 - Funding Information:
This paper was funded by the Juvenile Diabetes Research Foundation (JDRF 2-SRA-2021-1078-S-B) and Vivian L. Smith Foundation.
Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022/5/29
Y1 - 2022/5/29
N2 - Introduction: Cell transplantation is a promising curative therapeutic strategy whereby impaired organ function can be restored without the need for whole-organ transplantation. A key challenge in allotransplantation is the requirement for life-long systemic immunosuppression to prevent rejection, which is associated with serious adverse effects such as increased risk of opportunistic infections and the development of neoplasms. This challenge underscores the urgent need for novel strategies to prevent graft rejection while abrogating toxicity-associated adverse events. Areas covered: We review recent advances in immunoengineering strategies for localized immunomodulation that aim to support allograft function and provide immune tolerance in a safe and effective manner. Expert opinion: Immunoengineering strategies are tailored approaches for achieving immunomodulation of the transplant microenvironment. Biomaterials can be adapted for localized and controlled release of immunomodulatory agents, decreasing the effective dose threshold and frequency of administration. The future of transplant rejection management lies in the shift from systemic to local immunomodulation with suppression of effector and activation of regulatory T cells, to promote immune tolerance.
AB - Introduction: Cell transplantation is a promising curative therapeutic strategy whereby impaired organ function can be restored without the need for whole-organ transplantation. A key challenge in allotransplantation is the requirement for life-long systemic immunosuppression to prevent rejection, which is associated with serious adverse effects such as increased risk of opportunistic infections and the development of neoplasms. This challenge underscores the urgent need for novel strategies to prevent graft rejection while abrogating toxicity-associated adverse events. Areas covered: We review recent advances in immunoengineering strategies for localized immunomodulation that aim to support allograft function and provide immune tolerance in a safe and effective manner. Expert opinion: Immunoengineering strategies are tailored approaches for achieving immunomodulation of the transplant microenvironment. Biomaterials can be adapted for localized and controlled release of immunomodulatory agents, decreasing the effective dose threshold and frequency of administration. The future of transplant rejection management lies in the shift from systemic to local immunomodulation with suppression of effector and activation of regulatory T cells, to promote immune tolerance.
KW - Local immunosuppression
KW - cell therapy
KW - immunomodulation
KW - long-acting drug delivery
UR - http://www.scopus.com/inward/record.url?scp=85131333375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131333375&partnerID=8YFLogxK
U2 - 10.1080/17425247.2022.2076834
DO - 10.1080/17425247.2022.2076834
M3 - Article
C2 - 35588058
AN - SCOPUS:85131333375
VL - 19
SP - 1
EP - 16
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
SN - 1742-5247
IS - 5
ER -